Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.75% | 74.95% | -0.21% | -48.29% | 0.47% |
| Total Depreciation and Amortization | -2.75% | 0.91% | 0.21% | -10.22% | -0.47% |
| Total Amortization of Deferred Charges | -2.75% | 19.70% | 0.21% | 49.56% | -0.48% |
| Total Other Non-Cash Items | 2.75% | -130.06% | 0.21% | 223.40% | -0.47% |
| Change in Net Operating Assets | -2.73% | -78.35% | 0.20% | 126.64% | 0.47% |
| Cash from Operations | 2.75% | -198.72% | 0.21% | 147.15% | 0.47% |
| Capital Expenditure | 2.75% | -46.30% | -0.21% | -51.83% | 0.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.20% | -- | -- |
| Other Investing Activities | 2.75% | -144.77% | -0.21% | -122.70% | -0.47% |
| Cash from Investing | 2.75% | -232.53% | -0.21% | -120.66% | -0.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -10.54% | 0.00% | 85.39% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | 0.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -18.65% | 0.00% | -37.06% | 0.00% |
| Cash from Financing | 2.76% | -175.28% | 0.26% | 101.75% | 0.47% |
| Foreign Exchange rate Adjustments | -2.76% | 136.81% | 0.22% | 149.84% | 0.47% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.75% | -6,913.82% | 0.22% | -94.89% | -0.47% |